Document is current
Any future updates will be listed below
-
Authors
Cortes, Jorge E. https://orcid.org/0000-0002-8636-1071
Lin, Tara L.
Uy, Geoffrey L.
Ryan, Robert J.
Faderl, Stefan
Lancet, Jeffrey E.
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 6 May 2021
Accepted: 25 June 2021
First Online: 13 July 2021
Declarations
:
: The study protocol and all amendments were approved by the institutional review board or independent ethics committee at each study site, and all patients provided written informed consent prior to study participation.
: Not applicable.
: J.E.C. has received consulting fees from Astellas Pharma, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, and Pfizer, and research funding from Arog, Astellas Pharma, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, and Pfizer. T.L.L. has received institutional research funding from AbbVie, Aptevo, Astellas Pharma, Bio-Path Holdings, Celgene, Celyad, Genentech-Roche, Gilead Sciences, Incyte, Jazz Pharmaceuticals, Mateon Therapeutics, Ono Pharmaceuticals, Pfizer, Prescient Therapeutics, Seattle Genetics, Tolero Pharmaceuticals, and Trovagene. G.L.U. has received consulting fees from Jazz Pharmaceuticals and Genentech, and honoraria from Astellas Pharma. R.J.R. and S.F. are employees of and hold stock ownership/options in Jazz Pharmaceuticals. J.E.L. has received consulting fees from Jazz Pharmaceuticals, Agios, Pfizer, and Daiichi Sankyo.
